3-hydroxyflavanone
Description
3-hydroxyflavanone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3'-hydroxyflavanone : A monohydroxyflavanone in which the hydroxy group is located at position 3'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3534982 |
CHEMBL ID | 485021 |
CHEBI ID | 48022 |
SCHEMBL ID | 5088596 |
MeSH ID | M0443191 |
Synonyms (33)
Synonym |
---|
TIMTEC1_006574 |
3'-hydroxyflavanone |
3'-hydroxy flavanone |
2-(3-hydroxyphenyl)-2,3-dihydro-4h-chromen-4-one |
2-(3-hydroxyphenyl)chroman-4-one |
CHEBI:48022 , |
MLS001360502 |
smr001223897 |
HMS1552K18 |
CHEMBL485021 |
2-(3-hydroxyphenyl)-2,3-dihydrochromen-4-one |
H1025 |
92496-65-6 |
ST058458 |
HMS3040B14 |
3-hydroxyflavanone |
AKOS015856154 |
SCHEMBL5088596 |
JVSPTYZZNUXJHN-UHFFFAOYSA-N |
4h-1-benzopyran-4-one, 2,3-dihydro-2-(3-hydroxyphenyl)- |
unii-5o4my88w2v |
5O4MY88W2V , |
3'-hydroxyflavanone, (+/-)- |
2,3-dihydro-2-(3-hydroxyphenyl)-4h-1-benzopyran-4-one |
mfcd00017738 |
3''-hydroxyflavanone |
3''''-hydroxyflavanone |
bdbm50488649 |
DTXSID1022344 |
Q27120908 |
D90992 |
DTXSID50393419 |
CS-0330266 |
Roles (1)
Role | Description |
---|---|
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
---|---|
monohydroxyflavanone | Any hydroxyflavanone carrying a single hydroxy substituent. |
3'-hydroxyflavanones | Any hydroxyflavanone with a hydroxy substituent at position 3' of the phenyl ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (7)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
Nrf2 | Homo sapiens (human) | Potency | 15.8489 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 19.9526 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 27.5110 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
P53 | Homo sapiens (human) | Potency | 11.2202 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 89.1251 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (18)
Molecular Functions (10)
Process | via Protein(s) | Taxonomy |
---|---|---|
RNA polymerase II cis-regulatory region sequence-specific DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
double-stranded DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
RNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
mRNA 3'-UTR binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
lipid binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
identical protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
pre-mRNA intronic binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
molecular condensate scaffold activity | TAR DNA-binding protein 43 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Ceullar Components (9)
Process | via Protein(s) | Taxonomy |
---|---|---|
intracellular non-membrane-bounded organelle | TAR DNA-binding protein 43 | Homo sapiens (human) |
nucleus | TAR DNA-binding protein 43 | Homo sapiens (human) |
nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
perichromatin fibrils | TAR DNA-binding protein 43 | Homo sapiens (human) |
mitochondrion | TAR DNA-binding protein 43 | Homo sapiens (human) |
cytoplasmic stress granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
nuclear speck | TAR DNA-binding protein 43 | Homo sapiens (human) |
interchromatin granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
chromatin | TAR DNA-binding protein 43 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Bioassays (20)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID423365 | Binding affinity to Enterococcus faecalis KAS3 by fluorescence quenching analysis | 2009 | Journal of natural products, Apr, Volume: 72, Issue:4 | Screening of flavonoids as candidate antibiotics against Enterococcus faecalis. |
AID423362 | Antimicrobial activity against Enterococcus faecalis after 20 hrs by broth microdilution method | 2009 | Journal of natural products, Apr, Volume: 72, Issue:4 | Screening of flavonoids as candidate antibiotics against Enterococcus faecalis. |
AID353304 | Increase in EGR1 mRNA expression in human HeLa cells after 1 hr by Western blotting | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8 | Relationships between the structures of flavanone derivatives and their effects in enhancing early growth response-1 gene expression. |
AID423363 | Antimicrobial activity against vancomycin-resistant Enterococcus faecalis after 20 hrs by broth microdilution method | 2009 | Journal of natural products, Apr, Volume: 72, Issue:4 | Screening of flavonoids as candidate antibiotics against Enterococcus faecalis. |
AID353303 | Increase in EGR1 mRNA expression in human HEK293 cells at 20 ug/mL after 6 to 12 hrs by dual-glo luciferase assay relative to control | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8 | Relationships between the structures of flavanone derivatives and their effects in enhancing early growth response-1 gene expression. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (6.25) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (31.25) | 29.6817 |
2010's | 8 (50.00) | 24.3611 |
2020's | 2 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.41
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.41) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |